PCSK9 and hepatocellular carcinoma: Overexpressing Proprotein-Convertase-Subtilisin-Kexin Type-9 (PCSK9) promotes the lysosomal degradation of LDLR [30], which causes hypercholesterolemia and eventually HCC [31].